Wells Fargo & Co Reaffirms Buy Rating for Jazz Pharmaceuticals (JAZZ)
Several other research analysts have also commented on JAZZ. Cantor Fitzgerald reaffirmed a buy rating and set a $201.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday. BidaskClub lowered shares of Jazz Pharmaceuticals from a sell rating to a strong sell rating in a research note on Wednesday, September 19th. Morgan Stanley lowered shares of Jazz Pharmaceuticals from an overweight rating to an equal weight rating and set a $183.00 price objective for the company. in a research note on Wednesday, July 11th. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, July 16th. Finally, Leerink Swann lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an outperform rating in a research note on Friday, August 17th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $191.94.
Shares of JAZZ stock traded up $3.38 on Wednesday, reaching $145.57. The company’s stock had a trading volume of 1,051,546 shares, compared to its average volume of 631,079. Jazz Pharmaceuticals has a 1 year low of $130.15 and a 1 year high of $184.00. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.62 and a current ratio of 4.29. The firm has a market cap of $8.47 billion, a PE ratio of 15.23, a price-to-earnings-growth ratio of 0.76 and a beta of 1.06.
In related news, CFO Matthew P. Young sold 700 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $176.05, for a total value of $123,235.00. Following the completion of the sale, the chief financial officer now directly owns 34,168 shares in the company, valued at $6,015,276.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patrick G. Enright sold 10,130 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $168.76, for a total value of $1,709,538.80. Following the completion of the sale, the director now owns 19,884 shares of the company’s stock, valued at $3,355,623.84. The disclosure for this sale can be found here. Insiders have sold 16,730 shares of company stock valued at $2,796,532 over the last three months. Insiders own 3.90% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in JAZZ. Stratos Wealth Partners LTD. bought a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at about $106,000. Tiverton Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at about $198,000. Moloney Securities Asset Management LLC bought a new position in Jazz Pharmaceuticals in the second quarter worth about $204,000. FDx Advisors Inc. bought a new position in Jazz Pharmaceuticals in the second quarter worth about $244,000. Finally, Cadence Capital Management LLC bought a new position in Jazz Pharmaceuticals in the third quarter worth about $263,000. Hedge funds and other institutional investors own 92.95% of the company’s stock.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
See Also: Why do companies engage in swaps?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.